This content is machine translated Smoldering multiple myeloma Daratumumab delays progression in smoldering multiple myeloma Smoldering multiple myeloma (SMM) is an asymptomatic premalignant precursor of active multiple myeloma (MM). Results of the presented phase III AQUILA study show that daratumumab significantly delays the progression of...…
View Post 3 min This content is machine translated Multiple Myeloma Approval of daratumumab in Switzerland At the beginning of this year, the first active immunotherapy directed against CD38 in refractory multiple myeloma was approved in Switzerland. The data from the two studies MMY2002 (SIRIUS) and…
View Post 3 min This content is machine translated Heavily pretreated multiple myeloma New therapeutic option: an antibody that targets CD38 Results from an ongoing phase II trial of the monoclonal antibody daratumumab were presented at the ASCO Congress. This targets the protein CD38, which is highly expressed on myeloma cells.…
